8 results on '"Hirsch, Alan T."'
Search Results
2. Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study.
- Author
-
Ding N, Kwak L, Ballew SH, Jaar B, Hoogeveen RC, Ballantyne CM, Sharrett AR, Folsom AR, Heiss G, Salameh M, Coresh J, Hirsch AT, Selvin E, and Matsushita K
- Subjects
- Biomarkers blood, Critical Illness, Diabetes Mellitus diagnosis, Diabetes Mellitus epidemiology, Diabetes Mellitus therapy, Diabetic Foot diagnosis, Diabetic Foot epidemiology, Diabetic Foot therapy, Disease Progression, Female, Glycation End Products, Advanced, Humans, Incidence, Ischemia diagnosis, Ischemia epidemiology, Ischemia therapy, Male, Middle Aged, Peripheral Arterial Disease diagnosis, Peripheral Arterial Disease epidemiology, Peripheral Arterial Disease therapy, Predictive Value of Tests, Prevalence, Prognosis, Prospective Studies, Risk Assessment, Risk Factors, Severity of Illness Index, Time Factors, United States epidemiology, Glycated Serum Albumin, Blood Glucose metabolism, Deoxyglucose blood, Diabetes Mellitus blood, Diabetic Foot blood, Fructosamine blood, Glycated Hemoglobin metabolism, Ischemia blood, Lower Extremity blood supply, Peripheral Arterial Disease blood, Serum Albumin metabolism
- Abstract
Background and Aims: Traditional glycemic markers, fasting glucose and hemoglobin A1c (HbA1c), predict incident peripheral artery disease (PAD). However, it is unknown whether nontraditional glycemic markers, fructosamine, glycated albumin, and 1,5-anhydroglucitol, are associated with PAD and whether these glycemic markers demonstrate particularly strong associations with severe PAD, critical limb ischemia (CLI)., Methods: We quantified the associations of these five glycemic markers with incident PAD (hospitalizations with PAD diagnosis or leg revascularization) in 11,634 ARIC participants using Cox regression models. Participants were categorized according to diabetes diagnosis and clinical cut-points of glycemic markers (nontraditional glycemic markers were categorized according to percentiles corresponding to the HbA1c cut-points)., Results: Over a median follow-up of 20.7 years, there were 392 cases of PAD (133 were CLI with tissue loss). HbA1c was more strongly associated with incident PAD than fasting glucose, with adjusted hazard ratios (HR) 6.00 (95% CI, 3.73-9.66) for diagnosed diabetes with HbA1c ≥ 7% and 3.53 (2.39-5.22) for no diagnosed diabetes with HbA1c ≥ 6.5% compared to no diagnosed diabetes with HbA1c <5.7%. Three nontraditional glycemic markers demonstrated risk gradients intermediate between HbA1c and fasting glucose and their risk gradients were substantially attenuated after adjusting for HbA1c. All glycemic markers consistently demonstrated stronger associations with CLI than PAD without CLI (p for difference <0.02 for all glycemic markers)., Conclusions: Nontraditional glycemic markers were associated with incident PAD independent of fasting glucose but not necessarily HbA1c. Our results also support the importance of glucose metabolism in the progression to CLI., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
3. PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories): Overview of Design and Rationale of an International Prospective Peripheral Arterial Disease Study.
- Author
-
Smolderen KG, Gosch K, Patel M, Jones WS, Hirsch AT, Beltrame J, Fitridge R, Shishehbor MH, Denollet J, Vriens P, Heyligers J, Stone MEd N, Aronow H, Abbott JD, Labrosciano C, Tutein-Nolthenius R, and A Spertus J
- Subjects
- Aged, Australia, Cardiovascular Agents adverse effects, Female, Health Status Indicators, Healthcare Disparities, Humans, Intermittent Claudication diagnosis, Intermittent Claudication physiopathology, Intermittent Claudication psychology, Life Style, Male, Middle Aged, Netherlands, Peripheral Arterial Disease diagnosis, Peripheral Arterial Disease physiopathology, Peripheral Arterial Disease psychology, Prospective Studies, Quality of Life, Registries, Risk Factors, Surveys and Questionnaires, Time Factors, Treatment Outcome, United States, Cardiovascular Agents therapeutic use, Exercise Therapy adverse effects, Health Status, Intermittent Claudication therapy, Multicenter Studies as Topic methods, Patient Outcome Assessment, Peripheral Arterial Disease therapy, Research Design, Vascular Surgical Procedures adverse effects
- Abstract
Background: Health status outcomes, including symptoms, functional status, and quality of life, are critically important outcomes from patients' perspectives. The PORTRAIT study (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories) was designed to prospectively define health status outcomes and examine associations between patients' characteristics and care to these outcomes among those presenting with new-onset or worsened claudication., Methods and Results: PORTRAIT screened 3637 patients with an abnormal ankle-brachial index and new, or worsened, claudication symptoms from 16 peripheral arterial disease (PAD) specialty clinics in the United States, the Netherlands, and Australia between June 2, 2011, and December 3, 2015. Of the 1608 eligible patients, 1275 (79%) were enrolled. Before treatment, patients were interviewed to obtain their demographics, PAD symptoms and health status, psychosocial characteristics, preferences for shared decision-making, socioeconomic, and cardiovascular risk factors. Patients' medical history, comorbidities, and PAD diagnostic information were abstracted from patients' medical records. Serial information about patients' health status, psychosocial, and lifestyle factors was collected at 3, 6, and 12 months by a core laboratory. Follow-up rates ranged from 84.2% to 91%. Clinical follow-up for PAD-related hospitalizations and major cardiovascular events is ongoing., Conclusions: PORTRAIT systematically collected serial PAD-specific health status data as a foundation for risk stratification, comparative effectiveness studies, and clinicians' adherence to quality-based performance measures., Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01419080., (© 2018 American Heart Association, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
4. Serum 25-hydroxyvitamin D is associated with incident peripheral artery disease among white and black adults in the ARIC study cohort.
- Author
-
Rapson IR, Michos ED, Alonso A, Hirsch AT, Matsushita K, Reis JP, and Lutsey PL
- Subjects
- Biomarkers blood, Female, Humans, Incidence, Male, Middle Aged, Multivariate Analysis, Peripheral Arterial Disease blood, Peripheral Arterial Disease diagnosis, Proportional Hazards Models, Prospective Studies, Risk Assessment, Risk Factors, Time Factors, United States epidemiology, Vitamin D blood, Vitamin D Deficiency blood, Vitamin D Deficiency diagnosis, Black or African American, Peripheral Arterial Disease ethnology, Vitamin D analogs & derivatives, Vitamin D Deficiency ethnology, White People
- Abstract
Background and Aims: Low 25-hydroxyvitamin D [25(OH)D] concentrations have been associated with peripheral artery disease (PAD). Prevalence of low 25(OH)D and PAD differ between whites and blacks. However, these associations have not been studied prospectively or in a population based cohort. We tested the hypothesis that low 25(OH)D is associated with greater risk of incident PAD in white and black adults., Methods: 25(OH)D was measured in serum collected at ARIC visit 2 (1990-1992). We followed 11,789 ARIC participants free of PAD at visit 2 through 2011 for incident PAD events. 25(OH)D (ng/mL) was categorized as deficient (<20), insufficient (20 to <30) or sufficient (≥30). PAD was defined by an ankle brachial index (ABI) of <0.9 at ARIC visits 3 or 4 or a hospital diagnosis with an ICD-9 code indicating PAD during follow-up. Analysis used multivariable-adjusted Cox proportional hazards regressions., Results: Over a mean follow-up of 17.1 years, 1250 incident PAD events were identified. 22% of whites and 61% of blacks were 25(OH)D deficient. After adjustment for demographic characteristics, the hazard ratio (95% CI) of PAD in participants with deficient versus sufficient 25(OH)D was 1.49 (1.26, 1.76). Inclusion of BMI, physical activity, and smoking status attenuated the association [1.25 (1.06, 1.48)]. The association between 25(OH)D and PAD was qualitatively stronger in blacks (p for interaction = 0.20)., Conclusions: Deficient 25(OH)D was associated with increased risk of PAD in black and white participants. Whether treatment of low vitamin D through supplementation or modest sunlight exposure prevents PAD is unknown., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
5. The Cutaneous, Net Clinical, and Health Economic Benefits of Advanced Pneumatic Compression Devices in Patients With Lymphedema.
- Author
-
Karaca-Mandic P, Hirsch AT, Rockson SG, and Ridner SH
- Subjects
- Adult, Aged, Ambulatory Care statistics & numerical data, Female, Hospitalization statistics & numerical data, Humans, Lymphedema economics, Lymphedema etiology, Male, Managed Care Programs economics, Middle Aged, Multivariate Analysis, Regression Analysis, Retrospective Studies, Treatment Outcome, United States, Young Adult, Health Care Costs, Intermittent Pneumatic Compression Devices economics, Lymphedema therapy, Neoplasms complications
- Abstract
Importance: The prevalence and clinical burden of lymphedema is known to be increasing. Nevertheless, evidence-based comparative effectiveness data regarding lymphedema therapeutic interventions have been poor., Objective: To examine the impact of an advanced pneumatic compression device (APCD) on cutaneous and other clinical outcomes and health economic costs in a representative privately insured population of lymphedema patients., Design, Setting, and Participants: Retrospective analysis of a deidentified private insurance database from 2007 through 2013, and multivariate regression analysis comparing outcomes for the 12 months before and after APCD purchase, adjusting for baseline patient characteristics. Patients with lymphedema who received an APCD who were commercially insured and Medicare managed care enrollees from a large, national US managed care health insurer. The study population was evaluated as cancer-related and non-cancer-related lymphedema cohorts., Intervention: Receipt of an APCD., Main Outcomes and Measures: Rates of cellulitis, use of lymphedema-related manual therapy, outpatient hospital visits, and inpatient hospitalizations. Lymphedema-related direct costs were measured for home health care, hospital outpatient care, office visits, emergency department use, and inpatient care., Results: The study sample included 718 patients (374 in the cancer cohort and 344 in the noncancer cohort). In both cohorts, use of an APCD was associated with similar reductions in adjusted rates of cellulitis episodes (from 21.1% to 4.5% in the cancer cohort and 28.8% to 7.3% in the noncancer cohort; P < .001 for both), lymphedema-related manual therapy (from 35.6% to 24.9%in the cancer cohort and 32.3% to 21.2% in the noncancer cohort; P < .001 for both), and outpatient visits (from 58.6% to 41.4% in the cancer cohort and 52.6% to 31.4% in the noncancer cohort; P < .001 for both). Among the cancer cohort, total lymphedema-related costs per patient, excluding medical equipment costs, were reduced by 37% (from $2597 to $1642, P = .002). The corresponding decline in costs for the noncancer cohort was 36% (from $2937 to $1883, P = .007)., Conclusions and Relevance: The study found an association between significant reductions in episodes of cellulitis (cancer vs noncancer cohorts) and outpatient care and costs of APCD acquisition within a 1-year time frame in patients with both cancer-related and non-cancer-related lymphedema.
- Published
- 2015
- Full Text
- View/download PDF
6. Cost-effectiveness of supervised exercise, stenting, and optimal medical care for claudication: results from the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) trial.
- Author
-
Reynolds MR, Apruzzese P, Galper BZ, Murphy TP, Hirsch AT, Cutlip DE, Mohler ER 3rd, Regensteiner JG, and Cohen DJ
- Subjects
- Ambulatory Care economics, Aortic Diseases diagnosis, Aortic Diseases physiopathology, Constriction, Pathologic, Cost-Benefit Analysis, Drug Costs, Endovascular Procedures adverse effects, Exercise Therapy adverse effects, Hospital Costs, Humans, Intermittent Claudication diagnosis, Intermittent Claudication physiopathology, Life Expectancy, Models, Economic, Peripheral Arterial Disease diagnosis, Peripheral Arterial Disease physiopathology, Quality of Life, Quality-Adjusted Life Years, Time Factors, Treatment Outcome, United States, Vascular Patency, Aortic Diseases economics, Aortic Diseases therapy, Cardiovascular Agents economics, Cardiovascular Agents therapeutic use, Endovascular Procedures economics, Endovascular Procedures instrumentation, Exercise Therapy economics, Health Care Costs, Iliac Artery physiopathology, Intermittent Claudication economics, Intermittent Claudication therapy, Peripheral Arterial Disease economics, Peripheral Arterial Disease therapy, Stents economics
- Abstract
Background: Both supervised exercise (SE) and stenting (ST) improve functional status, symptoms, and quality of life compared with optimal medical care (OMC) in patients with claudication. The relative cost-effectiveness of these strategies is not well defined., Methods and Results: The Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) study randomized patients with claudication due to aortoiliac stenosis to a 6-month SE program, to ST, or to OMC. Participants who completed 6-month follow-up (n=98) were included in a health economic analysis through 18 months. Costs were assessed using resource-based methods and hospital billing data. Quality-adjusted life-years were estimated using the EQ-5D. Markov modeling based on the in-trial results was used to explore the impact of assumptions about the longer term durability of observed differences in quality of life. Through 18 months, mean healthcare costs were $5178, $9804, and $14 590 per patient for OMC, SE, and ST, respectively. Measured quality-adjusted life-years through 18 months were 1.04, 1.16, and 1.20. In our base case analysis, which assumed that observed differences in quality of life would dissipate after 5 years, the incremental cost-effectiveness ratios were $24 070 per quality-adjusted life-year gained for SE versus OMC, $41 376 for ST versus OMC, and $122 600 for ST versus SE. If the treatment effect of ST was assumed to be more durable than that of SE, the incremental cost-effectiveness ratio for ST versus SE became more favorable., Conclusions: Both SE and ST are economically attractive by US standards relative to OMC for the treatment of claudication in patients with aortoiliac disease. ST is more expensive than SE, with uncertain incremental benefit., Clinical Trial Registration Url: www.clinicaltrials.gov, Unique identifier: NCT00132743., (© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.)
- Published
- 2014
- Full Text
- View/download PDF
7. The impact of prolonged lower limb ischemia on amputation, mortality, and functional status: the FRIENDS registry.
- Author
-
Duval S, Keo HH, Oldenburg NC, Baumgartner I, Jaff MR, Peacock JM, Tretinyak AS, Henry TD, Luepker RV, and Hirsch AT
- Subjects
- Aged, Aged, 80 and over, Cause of Death trends, Female, Follow-Up Studies, Humans, Ischemia mortality, Male, Prognosis, Retrospective Studies, Risk Factors, Survival Rate trends, United States epidemiology, Amputation, Surgical mortality, Ischemia surgery, Lower Extremity blood supply, Registries, Risk Assessment methods
- Abstract
Background: Peripheral artery disease (PAD) is a major cause of cardiovascular ischemic events and amputation. Knowledge gaps exist in defining and measuring key factors that predict these events. The objective of this study was to assess whether duration of limb ischemia would serve as a major predictor of limb and patient survival., Methods: The FReedom from Ischemic Events: New Dimensions for Survival (FRIENDS) registry enrolled consecutive patients with limb-threatening peripheral artery disease at a single tertiary care hospital. Demographic information, key clinical care time segments, functional status and use of revascularization, and pharmacotherapy data were collected at baseline, and vascular ischemic events, cardiovascular mortality, and all-cause mortality were recorded at 30 days and 1 year., Results: A total of 200 patients with median (interquartile range) age of 76 years (65-84 years) were enrolled in the registry. Median duration of limb ischemia was 0.75 days for acute limb ischemia (ALI) and 61 days for chronic critical limb ischemia (CLI). Duration of limb ischemia of <12, 12 to 24, and >24 hours in patients with ALI was associated with much higher rates of first amputation (P = .0002) and worse amputation-free survival (P = .037). No such associations were observed in patients with CLI., Conclusions: For individuals with ischemic symptoms <14 days, prolonged limb ischemia is associated with higher 30-day and 1-year amputation, systemic ischemic event rates, and worse amputation-free survival. No such associations are evident for individuals with chronic CLI. These data imply that prompt diagnosis and revascularization might improve outcomes for patients with ALI., (Copyright © 2014 Mosby, Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
8. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population.
- Author
-
Nehler MR, Duval S, Diao L, Annex BH, Hiatt WR, Rogers K, Zakharyan A, and Hirsch AT
- Subjects
- Adult, Aged, Aged, 80 and over, Comorbidity, Critical Illness, Disease Progression, Female, Heart Failure epidemiology, Humans, Incidence, Ischemia diagnosis, Male, Middle Aged, Multivariate Analysis, Odds Ratio, Peripheral Arterial Disease diagnosis, Prevalence, Renal Insufficiency epidemiology, Retrospective Studies, Risk Assessment, Risk Factors, Stroke epidemiology, Time Factors, United States epidemiology, Ischemia epidemiology, Medicaid, Medicare, Peripheral Arterial Disease epidemiology
- Abstract
Background: Critical limb ischemia (CLI) represents the most severe clinical manifestation of peripheral arterial disease (PAD) and is the major cause of ischemic amputation in the United States. Risk factors and the associated incidence and prevalence of CLI have not been well described in the general population. This study describes the risk factors for PAD progression to CLI and estimates the annual incidence and prevalence of CLI in a representative United States patient cohort., Methods: This was a retrospective cohort analysis of adults with commercial, Medicare supplemental, or Medicaid health insurance who had at least one PAD or CLI health care claim from January 1, 2003, through December 31, 2008, and 12 months of continuous coverage. Two subgroups of CLI presentation were identified: primary CLI (patients without any prior PAD or subsequent PAD diagnostic code >30 days after CLI diagnostic code) and secondary CLI (patients with prior PAD or subsequent PAD diagnostic codes ≤30 days of a CLI diagnostic code). Patterns of presentation, annual incidence, and prevalence of CLI were stratified by health care plan. Risk factors for progression to CLI were compared by presentation type., Results: From 2003 to 2008, the mean annual incidence of PAD was 2.35% (95% confidence interval [CI], 2.34%-2.36%) and the incidence of CLI was 0.35% (95% CI, 0.34%-0.35%) of the eligible study population, with primary and secondary presentations occurring at similar rates. The mean annualized prevalence of PAD was 10.69% (95% CI, 10.67%10.70%) and the mean annualized prevalence of CLI was 1.33% (95% CI, 1.32%-1.34%) of the eligible study population, and two-thirds of the cases presented as secondary CLI. CLI developed in 11.08% (95% CI, 11.30%-11.13%) of patients with PAD. A multivariable model demonstrated that diabetes, heart failure, stroke, and renal failure were stronger predictors of primary rather than secondary CLI presentation., Conclusions: These data establish new national estimates of the incidence and prevalence of CLI and define key risk factors that contribute to primary or secondary presentations of CLI within a very large contemporary insured population cohort in the United States., (Published by Mosby, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.